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Abstract
Introduction: Interleukin (IL)-36 refers to three related IL-1 family cytokines, IL-36a, IL-36b, and IL-36g, that bind to
the IL-36 receptor (IL-36R). IL-36 exerts proinflammatory effects in skin and lung and stimulates T cell responses. In
the present study, we examined the expression and function of IL-36R and its ligands in experimental arthritis.
Methods: Collagen-induced arthritis (CIA), antigen-induced arthritis (AIA), and K/BxN serum transfer-induced
arthritis were induced according to standard protocols. Messenger RNA levels for IL-36R and its ligands in the joints
of mice with CIA were determined by RT-qPCR. Mice with CIA were injected with a blocking monoclonal anti-IL-
36R, a blocking anti-IL-1RI, or their isotype-matched control antibodies at the time of arthritis onset. Anti-IL-36R or
control antibodies were also injected at the time of AIA induction. Finally, IL-36R-deficient mice were examined in
AIA and serum transfer-induced arthritis. The development and severity of arthritis were assessed by clinical and
histological scoring.
Results: IL-36R, IL-36Ra and IL-36g mRNA were detected in the joints of mice with CIA, but their levels did not
correlate with arthritis severity. As opposed to anti-IL-1RI antibody treatment, the injection of an anti-IL-36R
antibody was devoid of effect on the development and severity of CIA. The severity of joint inflammation and
structural damage in AIA was also unaltered by anti-IL-36R antibody treatment. Finally, the severity of AIA and K/
BxN serum transfer-induced arthritis was similar in IL-36R-deficient and wild-type mice.
Conclusions: The development and severity of experimental arthritis are independent of IL-36R signaling.
Introduction
The IL-1 family of cytokines includes three well-
described agonists with pro-inflammatory properties,
namely IL-1a, IL-1b, and IL-18, as well as the IL-1
receptor antagonist (IL-1Ra), a naturally occurring inhi-
bitor that regulates the biological activities of IL-1a and
IL-1b. In addition, seven novel IL-1 family members
have been identified on the basis of their sequence
homology, three-dimensional protein structure, gene
location and receptor binding profile [1-7]. These pro-
teins are now termed IL-36Ra, IL-36a, IL-36b, IL-36g,
IL-37, IL-38 and IL-33 (previously known as IL-1F5, IL-
1F6, IL-1F8, IL-1F9, IL-1F7, IL-1F10 and IL-1F11,
respectively) [8]. IL-36a, IL-36b and IL-36g bind to a
heterodimeric receptor consisting of the IL-36 receptor
(IL-36R) subunit (previously called IL-1Rrp2) and the
IL-1 receptor accessory protein (IL-1RAcP), a common
receptor subunit, which is involved also in IL-1 and IL-
33 signaling [9]. Like IL-1, IL-18 or IL-33, IL-36 cyto-
kines activate nuclear factor (NF)-B, c-Jun N-terminal
kinase (JNK) and extracellular signal-regulated kinase
(ERK)-1/2 intra-cellular signaling pathways upon recep-
tor binding [9]. IL-36Ra binds to IL-36R but does not
induce any cellular response. It prevents the interaction
of IL-36a, IL-36b and IL-36g with IL-36R and thus, acts
as a natural inhibitor [10].
IL-36R and its ligands are expressed in skin and inter-
nal epithelial tissues exposed to pathogens, such as tra-
chea, lung and esophagus, but also in the brain, gut and
kidney [5,11-13]. Several studies suggest that IL-36
exerts pro-inflammatory effects contributing to the
pathogenesis of psoriasis and lung inflammation
[11,14-16]. In addition, we recently described that IL-36
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stimulates cytokine production by dendritic cells (DC)
more efficiently than other IL-1 family members [17]. In
addition, IL-36 acts in synergy with IL-12 to induce the
polarization of naïve CD4+ T cells into T helper (Th)1
cells [18]. Consistently, IL-36 enhances Th1 responses
in vivo [17,18]. These observations led to the hypothesis
that IL-36, being expressed in epithelia and in immune
cells, might act as an early danger signal to activate cells
of the innate and adaptive immune system. Depending
on the context, this activation might enhance host
responses against pathogens, or amplify pathological
inflammation, as illustrated by the occurrence of gener-
alized pustular psoriasis in patients with mutated IL-
36Ra [19,20].
In a previous study, we examined the role of the IL-36
cytokines in human arthritis. IL-36a and IL-36b mRNA
were detected in synovial biopsies of patients with rheu-
matoid arthritis (RA). Human synovial fibroblasts (hSF)
and articular chondrocytes (hAC) expressed IL-36R and
produced pro-inflammatory mediators, such as IL-6, IL-
8 and nitric oxide (NO) in response to stimulation by
recombinant IL-36b, but this effect was of a much lower
magnitude than that induced by IL-1. In hSF, IL-36b
mRNA levels were enhanced upon stimulation with IL-
1b and/or TNF-a, while IL-36b mRNA expression was
constitutive in hAC. IL-36b protein levels were detect-
able in the synovial fluid and in the serum of patients
with RA. However, there was no correlation between
serum levels of IL-36b and markers of the acute-phase
response [21]. A recent study reported increased IL-36a
protein expression in the synovial tissue of patients with
RA and psoriatic arthritis (PsA), as compared to
osteoarthritis (OA). In this work, IL-36a expression was
mainly associated with CD138+ plasma cells. IL-36R and
IL-36Ra expression was similar in RA, PsA and OA
synovium [22].
In the present study, we examined expression of IL-36
and IL-36R in joints of mice with collagen-induced
arthritis (CIA), and investigated the role of IL-36R signal-
ing in three different experimental models of arthritis.
Materials and methods
Mice
C57BL/6 mice were obtained from Janvier (Le Genest-
St-Isle, France) or Charles River Laboratories (Wilming-
ton, MA, USA) and were used between 9 and 13 weeks
of age. DBA/1 mice were also obtained from Janvier and
were used between 10 and 12 weeks of age. BALB/c
mice were obtained from Jackson Laboratories (Bar Har-
bor, ME, USA) and were used between 8 and 10 weeks
of age. IL-36R-deficient mice (IL-36R-/-) were back-
crossed seven times into a pure C57BL/6J genetic back-
ground using a marker-assisted selection protocol
(MASP) approach and were used between 8 and 12
weeks of age [23,24]. All mice were housed under con-
ventional conditions, and water and standard laboratory
chow were provided ad libitum. Animal studies were
conducted under protocols approved by the Geneva
Cantonal Authority for Animal Experiments (Geneva,
Switzerland; licenses 31.1.1005/3351/2 and 31.1.1005/
3834/2) or by the Institutional Animal Care and Use
Committee at Amgen Inc. (Seattle, WA, USA).
RNA extraction and determination of gene
expression by quantitative real-time RT-PCR
Ankles were collected during the early phase of CIA
(between days 22 and 30 after the first immunization)
from paws with different severity of arthritis. Total RNA
was extracted with Trizol reagent (Invitrogen AG, Basel,
Switzerland) and reverse-transcribed using SuperScript II
Reverse transcriptase (Invitrogen Life Technologies, Basel,
Switzerland). The mRNA levels for genes of interest were
examined by quantitative RT-PCR using the iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA, USA) according
to a standard protocol (40 cycles, annealing temperature
60°C). All primer sequences are listed in Table 1. Relative
levels of mRNA expression were normalized to glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) mRNA
levels using a comparative method (2-ΔCt). Non-reverse-
transcribed RNA samples and water were included as
negative controls.
Antibodies and recombinant cytokine
The following monoclonal antibodies were produced by
Amgen Inc.: a rat IgG2a anti-mouse IL-36R antibody
(M616) and a murinized chimeric (hamster-mouse)
IgG1 anti-mouse IL-1RI antibody (M147) directed
against the extracellular domain of mouse IL-36R and
IL-1RI, respectively; two rat IgG2a isotype control
Table 1 Sequences of primers used for quantitative real-
time polymerase chain reaction
IL-36R forward 5’-AAACACCTAGCAAAAGCCCAG-3’
IL-36R reverse 5’-AGACTGCCCGATTTTCCTATG-3’
IL-1R1 forward 5’- GAGTTACCCGAGGTCCAGTGG-3’
IL-1R1 reverse 5’-GAGGGCTCAGGATAACAGG-3’
IL-36g forward 5’- AGAGTAACCCCAGTCAGCGTG-3’
IL-36g reverse 5’- AGGGTGGTGGTACAAATCCAA-3’
IL-1b forward 5’-TGTGAAATGCCACCTTTTGA-3’
IL-1b reverse 5’-GTGCTCATGTCCTCATCCTG-3’
IL-36Ra forward 5’- CCTGCTTTCTACTTAGGTCTCAAAT-3’
IL-36Ra reverse 5’- GCTCCTCTGTCTCTCTATCCTCTAT-3’
IL-1Ra forward 5’- GGGATACTAACCAGAAGACC-3’
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antibodies (4G8 and M10) and a mouse IgG1 isotype
control antibody (4D2). We also used a rat IgG2a iso-
type control (9B5; anti-human CD44) antibody provided
by Prof. Beat Imhof (University of Geneva School of
Medicine, Geneva, Switzerland). Recombinant murine
IL-36g was produced at Amgen Inc. as an N-terminal
truncated form displaying high biological activity [10].
Assessment of in vivo blocking activity of the monoclonal
anti-IL-36R antibody
The ability of the anti-mouse IL-36R antibody (M616)
to inhibit the biologic effects of IL-36R agonists was
tested in vivo. BALB/c mice were pre-treated intrana-
sally (i.n.) with the anti-mouse IL-36R antibody (50 μg/
mouse), an isotype- matched control antibody (M10; 50
μg/mouse) or PBS 2 h prior to i.n. challenge with
recombinant murine IL-36g (1 μg/mouse) on days 0, 1
and 2. Bronchoalveolar lavage (BAL) fluids recovered
from mice 4 h after the last injection on day 2 were
used to assess total and differential cell counts and to
measure chemokine (CCL20, CCL11 and CCL24) pro-
tein levels.
Bronchoalveolar lavage and differential cell counts
Mice were anesthetized with avertin (300 μL (5% solu-
tion)/mouse; Sigma-Aldrich; St Louis, MO, USA). BAL
fluid was collected via endotracheal intubation using a
25 gavage needle with a 1 mm ball tip, by gently wash-
ing and aspirating 0.5 mL PBS solution twice. The 2 ×
0.5 mL BAL fluid samples were pooled for each animal
and centrifuged. The BAL fluid supernatant was imme-
diately diluted 1:1 with a PBS, 0.1% Tween 20 solution.
BAL sediments were re-suspended in PBS + 0.5% FBS
and 175 μL per sample were used for counting with the
ADVIA 120 Hematology system (Siemens Diagnostics,
Tarrytown, NY, USA) to obtain an automated total of
cell counts and differentials.
Collagen-induced arthritis
CIA was induced in male DBA/1 mice, as previously
described [25]. Blocking anti-IL-36R M616, anti-IL-1RI
M147 antibodies or their respective isotype-matched
control antibodies (4G8 and 4D2) were injected (150
μg/mouse intraperitoneally (i.p.)) every 2 to 3 days start-
ing on day 27 after the first immunization. Mice were
killed on day 41. During the course of CIA, arthritis
severity was assessed by clinical scoring using a 3-point
scale for each paw, as previously described [26].
Antigen-induced arthritis (AIA)
Male C57BL/6 mice were immunized intradermally (i.d.)
at the base of the tail with 100 μg of methylated BSA
(mBSA; Fluka, Buchs, Switzerland), emulsified in com-
plete Freund’s adjuvant (Difco, Basel, Switzerland)
containing 5 mg/mL Mycobacterium tuberculosis. On
day 7, a booster injection of 100 μg mBSA in incomplete
Freund’s adjuvant (Difco) was given at the base of the
tail. On day 21, arthritis was induced by intra-articular
injection of 100 μg mBSA in 10 μL PBS into the left
knee joint of mBSA-immunized mice, the right knee
being injected with sterile PBS alone. The anti-IL-36R
antibody M616 (150 μg/mouse, i.p.), the isotype-
matched control antibody 9B5 (150 μg/mouse, i.p.) or
PBS were injected 1 h before intra-articular mBSA injec-
tion. Mice were sacrificed 8 or 14 days after induction of
arthritis, the latter group receiving a second injection of
antibodies or PBS on day 4. The development of arthri-
tis was followed by measuring 99mTechnetium (Tc)
uptake in the knees on days 1, 3 and 7 after intra-articu-
lar mBSA injection, as previously described [27]. A sec-
ond AIA experiment was performed on adult male IL-
36R-/- and wild-type (WT) C57BL/6 mice. 99m Tc uptake
was measured in the knees on days 1, 3 and 7 after
intra-articular mBSA injection and the mice were killed
on day 8.
K/BxN serum transfer-induced arthritis and
clinical scoring
K/BxN serum was collected from 9-week old arthritic K/
BxN mice, as previously described [28]. The serum sam-
ples were pooled and stored at -80°C until use. K/BxN
serum transfer-induced arthritis was induced in adult
female IL-36R-/- and WT C57BL/6 mice by i.p. injection
of K/BxN serum (200 μL) on days 0 and 2. Mice were
scored clinically every day for the development of arthri-
tis using a semi-quantitative scoring system [29]. The
mice were sacrificed on day 6.
Histological grading of arthritis
At sacrifice, isolated joints (knees for CIA and AIA;
ankles for K/BxN serum transfer-induced arthritis) were
fixed in 10% formalin, decalcified in 15% ethylenediami-
netetraacetic acid (EDTA), and embedded in paraffin.
Serial sections (3 μm) were stained with H&E for evalua-
tion of inflammation or with toluidine blue to analyze
cartilage damage. Sections were scored by a pathologist
(CAS) in a blinded manner for arthritis severity by asses-
sing inflammation and joint destruction with a semi-
quantitative score, as described elsewhere [29].
Measurement of cytokine and chemokine levels
in serum, BAL fluids and tissue lysates
Serum, BAL fluids, and knee joints were collected at sacri-
fice. Total joint proteins were extracted as described pre-
viously [30]. Total protein concentrations were
determined using the DC Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA, USA), according to the manu-
facturer’s protocol. Chemokine (CCL20, CCL11, CCL24
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and CXCL-1) and cytokine (IL-1Ra, IL-6) protein levels in
serum, BAL and tissue lysates were determined using
commercial Duoset ELISA Development Systems from
R&D Systems (R&D Systems, Abingdon, UK).
Statistical analysis
One-way analysis of variance (ANOVA) followed by
two-tailed Student’s t-test was used for statistical analy-
sis of experiments involving more than two groups.
Two-tailed Student’s t-test was performed only when
the one-way ANOVA yielded statically significant
results. Differences in arthritis severity and in the num-
ber of affected paws at the end of the follow up were
evaluated using the Kruskal-Wallis test. P-values < 0.05
were considered significant.
Results
Expression of IL-36R, IL-36g and IL-36Ra in normal and
inflamed joints during CIA
We first examined expression of IL-36R and IL-36
ligands in the joints of mice with different severity of
CIA using RT-quantitative (q)PCR. IL-36R, IL-36g and
IL-36Ra mRNA were expressed in clinically unaffected
(clinical score = 0) and in inflamed joints (Figure 1A-C),
whereas IL-36a and IL-36b mRNA were undetectable
(data not shown). IL-36R, IL-36g and IL-36Ra mRNA
levels did not correlate with disease severity, but were
comparable to those found in normal skin, a tissue in
which IL-36 has been previously reported to play a
pathogenic role (data not shown) [11]. IL-36R expres-
sion was constitutive in the joints of naïve mice, while
IL-36g and IL-36Ra expression levels were at least one
order of magnitude lower than in joints of mice with
CIA (data not shown). For comparison, and in agree-
ment with previously published data, IL-1RI, IL-1b and
IL-1Ra mRNAs were present in inflamed joints of mice
with CIA (Figure 1D-F) with a significant correlation
between IL-1b mRNA levels and the severity of arthritis
[31].
Efficacy of a blocking monoclonal anti-IL-36R
antibody in vivo
To investigate the role of IL-36R signaling in experi-
mental arthritis, we used a blocking monoclonal rat
anti-mouse IL-36R antibody (M616). The neutralizing
efficacy of this antibody was first validated by examining
its ability to inhibit the biological effects of recombinant
(r) mouse IL-36g in vivo (Figure 2). We treated mice
intranasally with the anti-mouse IL-36R antibody, an
isotype-matched control antibody or PBS prior to chal-
lenge with rIL-36g. In agreement with previous data, we
observed that i.n. instillation of rIL-36g increased the
total leucocyte numbers and resulted in marked neutro-
philic infiltration in BAL fluids (Figure 2A) [15]. The
administration of rIL-36g also increased the protein
levels of several chemokines in BAL fluids, including
CCL20 and CCL11, as previously described, as well as
CCL24 (Figure 2B) and CXCL-1 (data not shown) [15].
Pre-treatment of mice with the anti-mouse IL-36R anti-
body inhibited the effects of rIL-36g (Figure 2), indicat-
ing that this monoclonal anti-IL-36R antibody efficiently
inhibits IL-36R signaling in vivo.
Treatment with a monoclonal anti-IL-36R antibody does
not modify the course of CIA
Consecutively, we tested the role of IL-36R signaling in
CIA using DBA/1 mice. We compared the effect of an i.
p. injected anti-IL-36R antibody, administered at disease
onset, with that of an isotype-matched control antibody.
An additional group of DBA/1 mice served a positive
control and was treated with a blocking anti-IL-1RI
antibody to compare the relative contributions of
IL-36R ligands and IL-1 cytokines (IL-1a and IL-1b) to
the development and severity of CIA. Treatment of
mice with the blocking anti-IL-36R antibody was devoid
of effect on the incidence (Figure 3A) or severity of CIA
(Figure 3B and 3C). In contrast, inhibition of IL-1RI sig-
naling resulted in marked attenuation of the disease.
Consistent with these results, histological examination at
the end of the experiment showed a complete protection
in mice treated with the anti-IL-1RI antibody, whereas
articular inflammation and structural damage were simi-
lar in mice injected with the anti-IL-36R or with iso-
type-matched control antibodies (Figure 3E and 3F).
Similarly, serum IL-6 levels were elevated in mice trea-
ted with the anti-IL-36R antibody or with isotype-
matched control antibodies, while circulating IL-6 was
undetectable in anti-IL-1RI antibody-treated mice (Fig-
ure 3D). Finally, the levels of different inflammatory
mediators, such as IL-6 and CXCL-1, were elevated in
the joints of anti-IL-36R antibody and isotype control
antibody-treated mice, while they were drastically
decreased in mice treated with the anti-IL-1RI antibody
(Figure 3G; data not shown). Taken together, our results
suggest that there is no major contribution of IL-36R
ligands to the development and severity of CIA.
The course of AIA is not modified by treatment of
wild-type mice with a monoclonal anti-IL-36R
antibody or in IL-36R-deficient mice
To extend our investigations to another model of arthri-
tis and mouse strain, we then analyzed the effect of the
anti-IL-36R antibody (M616) on the course of AIA in
C57BL/6 mice. The severity of AIA, as assessed by
99mTc uptake, was not altered by the treatment with the
anti-IL-36R antibody, initiated at the time of disease
induction, as compared to treatment with an isotype-
matched control antibody or with PBS (Figure 4A, upper
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Figure 1 Analysis of IL-36R, IL-36g and IL-36Ra mRNA expression in normal and inflamed joints during collagen-induced arthritis (CIA).
IL-36 receptor (IL-36 R) (A), IL-36g (B), IL-36R antagonist (IL-36Ra) (C), IL-1RI (D), IL-1b (E) and IL-1Ra (F) mRNAs levels were determined by
RT-qPCR in normal (clinical score = 0) or inflamed (low clinical scores: 0.5 to 1.5; high clinical scores: 2.0 to 3.0) ankles of type II collagen
(CII)-immunized DBA-1 mice in the first nine days after the appearance of clinical symptoms (early arthritis). (A-F) mRNA expression was
normalized to the amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Each data point represents a single mouse; horizontal
lines show the mean. *P < 0.05 versus score 0, as assessed by analysis of variance, followed by unpaired two-tailed Student’s t-test.
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panel). Accordingly, histological analysis of the paws on
days 8 and 14 of arthritis showed no difference in the
extent of articular inflammation and structural damage
between mice treated with the anti-IL-36R antibody and
the control groups (Figure 4A, lower panel). To further
examine the role of IL-36R signaling in the control of
joint inflammation in this model, AIA was induced in
IL-36R-/- and WT control mice. As shown in Figure 4B,
the severity of arthritis, assessed by Tc uptake and histo-
logical analysis did not differ between IL-36R-/- and WT
mice. Taken together, these data suggest that the IL-36/
IL-36R system is not of functional importance in AIA.
Incidence and severity of K/BxN serum transfer-induced
arthritis are not altered in IL-36R-deficient mice
CIA and AIA are dependent on active immunization
and are therefore influenced by alterations of the
adaptive immune response. To more specifically investi-
gate the involvement of IL-36R in the inflammatory
effector phase of arthritis, we used the passive K/BxN
serum transfer-induced model, which is independent of
the adaptive immune response in IL-36R-/- and WT
control mice. As shown in Figure 5, we observed no dif-
ference in the incidence and the severity of the disease
between IL-36R-/- and wild-type mice.
Discussion
This is the first study that examined in detail the
expression of IL-36 cytokines and their receptor, as well
as the role of IL-36R signaling in experimental arthritis.
IL-36R, IL-36g, and IL-36Ra mRNAs were expressed in
the joints of mice with CIA but, as opposed to IL-1b,
their levels did not correlate with the severity of articu-
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Figure 2 Efficacy of a blocking monoclonal anti-IL-36 receptor (R) antibody in vivo. BALB/c mice (n = 5/group) were pre-treated
intranasally (i.n.) with a rat IgG2a anti-mouse IL-36R antibody (M616; 50 μg/mouse; squares), an isotype control antibody (M10; 50 μg/mouse;
triangles) or PBS (circles) 2 h prior to i.n. challenge with recombinant IL-36g (1 μg/mouse) on days 0, 1 and 2. A fourth group of mice, used as
negative control, only received i.n. injection of PBS (inverted triangles). On day 2, bronchoalveolar lavage fluids recovered from mice 4 h after
the last injection were used to assess (A) total leucocyte and neutrophil counts and (B) chemokine (CCL20, CCL11 and CCL24) protein levels by
DuoSet ELISA. (A-B) Results are shown as individual values for each mouse (symbols) and mean values (lines). ***P < 0.001 versus isotype
control-treated mice, as assessed by unpaired two-tailed Student’s t-test.
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Figure 3 Treatment with a monoclonal anti-IL-36 receptor (R) antibody does not modify the course of collagen-induced arthritis (CIA).
CII-immunized mice (n = 10/group) were treated with anti-IL36R (M616, squares, white columns), anti-IL-1RI (M147, triangles, dashed columns) or
isotype-matched control antibodies (4G8 (circles, grey columns) for M616, 4D2 (triangles, black columns) for M147), as described in Materials and
methods. Results show the incidence of arthritis (A), the clinical severity of articular inflammation (B) and the number of arthritic paws (C) on
days 21 to 41. The systemic inflammatory response (D) was assessed by measuring circulating IL-6 levels on day 41 after the first immunization.
Joint sections from all mice were evaluated on day 41 for histological scores (E) and histological features (F). All sections were scored for
inflammation, cartilage erosion and neutrophil infiltration. Images are representative of H&E- or toluidine blue-stained sections of knee joints for
each group (original magnification × 10). (G) Levels of CXCL-1 (ng/mL) were determined by ELISA in ankle extracts of each mouse on day 41
and normalized by the total protein concentration (mg/mL). (B, C, E) Values are the mean ± standard error of the mean. ***P < 0.001, anti-IL-1RI
versus isotype control 4D2; &P < 0.05 and &&P < 0.01, anti-IL-1RI versus anti-IL-36R, as assessed by Kruskal-Wallis test (B and C) or by analysis of
variance (ANOVA), followed by unpaired two-tailed Student’s t-test (E). (D, G) Results are shown as individual values for each mouse (symbols)
and mean values (lines) **P < 0.01, anti-IL-1RI versus isotype control 4D2, as assessed by ANOVA, followed by unpaired two-tailed Student’s
t-test.
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Figure 4 The course of antigen-induced arthritis (AIA) is not modified by treatment with a monoclonal anti-IL-36 receptor (R)
antibody or in IL-36R-deficient mice. Time course of knee joint inflammation is shown in anti-IL-36R antibody-treated mice (A, upper panel)
and in IL-36R knockout (KO) mice (B, left panel) with AIA. Joint inflammation was measured by external gamma counting of 99mtechnetium (Tc)
accumulation on days 1, 3 and 7 after mBSA injection into the left knee. Results are expressed as the ratio of 99mTc uptake in the left arthritic
knee over the right non-inflamed knee. For each time point, the mean ± standard error of the mean (SEM) of the ratios is shown for anti-IL-36R
antibody (n = 7; triangles), 9B5 (rat IgG2a anti-human CD44) isotype-matched control antibody-treated mice (n = 7; gray circles), or PBS-treated
mice (n = 11; open circles), wild-type (WT) C57BL/6J mice (n = 9; black line) and IL-36R-/- mice (n = 7; dashed line). (A, lower panels; B, right
panel) Histological scores for synovial inflammation and cartilage degradation 8 and 14 days after intra-articular mBSA injection. Results shown
represent the mean ± SEM for anti-IL-36R antibody (n = 5 on day 8, n = 6 on day 14, black columns), 9B5 isotype control (n = 3 on day 8, n = 4
on day 14, hatched columns), PBS-treated mice (n = 3 on day 8, n = 4 on day 14, open columns) (A, lower panels), WT C57BL/6J mice (n = 9 on
day 8, white columns) and IL-36R-/- mice (n = 7 on day 8, black columns) (B, right panel).
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severity of CIA was markedly attenuated by the adminis-
tration of a blocking anti-IL-1RI antibody, but not by a
neutralizing anti-IL-36R antibody. Similarly, anti-IL-36R
antibody treatment did not modify disease severity in
AIA. Finally, data obtained in IL-36R-deficient mice
confirmed that the severity of arthritis was independent
of IL-36R signaling in AIA and K/BxN serum transfer-
induced arthritis, two experimental models that are
dependent and independent of adaptive immune
responses, respectively.
The role of adaptive immunity has been extensively
examined in CIA, in particular that of the cytokines pro-
duced by the different CD4+ Th cell subsets. The patho-
genic role of Th17 cells has been well demonstrated by
using neutralizing antibodies and il17a gene knockout
mice [32,33]. In contrast, Th1 responses exert more
complex effects during the course of CIA. Indeed, IFN-
g-/- and IFN-g R-/- mice exhibit a more severe form of
CIA than WT mice, most likely due to the absence of a
counter-regulatory effect of IFN-g on the expansion of
Th17 cells [34-36]. However, the injection of recombi-
nant IL-12 enhances the severity of CIA during the
induction phase, but attenuates the inflammatory pro-
cess when administered in established CIA. Consistent
with these findings, opposite phenotypes were observed
in mice injected with neutralizing anti-IL-12 antibodies
[37]. These data are in line with the early development
of antigen-specific IFN-g-producing T cells before the
occurrence of overt signs of arthritis, whereas IL-17 pro-
duction seems to increase later in the course of CIA
[30]. We have recently shown that IL-36 induces the
production of several cytokines and chemokines by bone
marrow-derived DCs, and in particular the production
of IL-12 [17]. Furthermore, IL-36 stimulates the polari-
zation of naïve mouse Th0 cells into IFN-g-producing
Th1 cells, and this effect is dependent on the presence
of IL-12 in vitro and in vivo. Of note, in the same condi-
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Figure 5 Incidence and severity of K/BxN serum transfer-induced arthritis are not reduced in IL-36 receptor (R) knockout (KO) mice.
Incidence of arthritis (A), arthritis severity scores (B) and the number of affected paws (C) are shown for WT (n = 10, black line) and IL-36R KO (n
= 7, dashed line) mice. (A and C) Results are shown as the mean ± standard error of the mean.
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contrast, IL-1 has previously been shown to markedly
stimulate the polarization of Th17 cells [38-40]. In
agreement with these findings, excessive IL-1 signaling
in IL-1Ra-deficient BALB/c mice is associated with the
development of polyarthritis related to the enhanced
production of IL-17 [41]. In addition, conditional mye-
loid-specific IL-1Ra-deficient mice had a more severe
form of CIA with increased IL-17 levels in the joints
and in cultured lymph node cells [30]. Taken together,
these findings suggest that IL-36 and IL-1 exert distinct
effects on Th cell responses that may, at least partly,
explain the differences observed in the development and
severity of CIA upon targeting IL-1RI or IL-36R. In
addition, as illustrated also by our results in the K/BxN
serum transfer-induced arthritis model, IL-1 and IL-36
may also exert distinct effects in the control of local
inflammatory responses in the joint.
The injection of a neutralizing anti-IL-36R antibody at
the time of arthritis induction did not modify the course
of disease in AIA. Furthermore, the severity of AIA was
not decreased in IL-36R-/- mice, indicating that IL-36R
signaling was also dispensable during the induction of
the immune response against mBSA. This result is con-
sistent with our previous data demonstrating normal
IFN-g production by antigen-specific T cells after immu-
nization of IL-36R-/- mice with Freund’s adjuvant, but
contrasts with the adjuvant effect of IL-36, as well as
with the decreased IFN-g production observed in IL-
36R-/- mice after infection with Bacillus Calmette-
Guérin (BCG) [17,18]. The explanation for these differ-
ences may lie in the very potent effect of the complete
Freund’s adjuvant, which is able to overcome the
absence of IL-36R signaling by stimulating a number of
other cytokines involved in Th1 polarization, such as IL-
12 and IL-18.
Finally, the severity of K/BxN serum transfer-induced
arthritis was not affected by IL-36R deficiency indicating
that the inflammatory effector phase of arthritis in this
model was also independent of IL-36. In contrast, IL-
1RI signaling is critically needed for the development of
K/BxN serum transfer-induced arthritis [42]. Accord-
ingly, we recently observed that administration of the
anti-IL-1RI antibody markedly decreased the severity of
serum transfer-induced arthritis (G. Palmer et al,
unpublished data). These findings point to marked dif-
ferences between IL-1 and IL-36 in the magnitude of
their stimulatory effects on the production of pro-
inflammatory mediators by human synovial fibroblasts
and articular chondrocytes [21].
In conclusion, our results indicate, that as opposed to
IL-1RI activation, IL-36R signaling is not involved in the
development of experimental arthritis in the three mod-
els examined. The role of IL-1 in Th17 differentiation,
as well as its potent stimulatory effects on resident joint
cells leading to local inflammation, neither of which are
shared by IL-36, may explain the differential involve-
ment of these two cytokines in arthritis.
Conclusions
Taken together with our previously published data on
IL-36 levels in synovial tissue and fluid samples from
RA patients, the results obtained here using three differ-
ent models of experimental arthritis suggest that the IL-
36/IL-36R pathway is unlikely to be involved in the
pathogenesis of RA.
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